Pharmaceuticals Africa

Africa Long-Acting HIV Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Africa Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $39.0 Mn Placeholder estimate
Estimate 2025 $47.4 Mn 1.6% of the global market
Projected 2034 $273.4 Mn 477% Adds $226.0 Mn over 9 forecast years
CAGR 2025–2034 21.5% Faster than 87% of 180 Pharmaceuticals markets here
Key players 4
  • Africa is 1.65% of the global market.
  • Among regions, the largest is North America at $1.48 Bn.
  • Fastest growing: APAC at 21.6% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$226.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $39.0 Mn — —
2025 (base) $47.4 Mn +$8.4 Mn —
2026 (forecast) $57.6 Mn +$10.2 Mn +21.5%
2027 (forecast) $70.0 Mn +$12.4 Mn +47.6%
2028 (forecast) $85.0 Mn +$15.0 Mn +79.4%
2029 (forecast) $103.3 Mn +$18.3 Mn +117.9%
2030 (forecast) $125.5 Mn +$22.2 Mn +164.8%
2031 (forecast) $152.4 Mn +$27.0 Mn +221.7%
2032 (forecast) $185.2 Mn +$32.8 Mn +290.9%
2033 (forecast) $225.0 Mn +$39.8 Mn +374.9%
2034 (forecast) $273.4 Mn +$48.4 Mn +477%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Long-Acting HIV Treatment Market Analysis at a glance
Market size, 2025$47.4 Mn placeholder estimate
Forecast, 2034$273.4 Mn placeholder estimate
Growth (CAGR), 2025–203421.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsUse, drug and end user (see all)
Key playersViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
Active clinical trials15 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Long-Acting HIV Treatment Market Analysis Executive Summary

Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.

Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).

Bar chart: Africa Long-Acting HIV Treatment market size, 2024–2034, placeholder estimates. $39.0 Mn in 2024, $47.4 Mn in 2025 and $273.4 Mn in 2034, 21.5% CAGR.
Africa Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Long-Acting HIV Treatment Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.

Competitive Landscape for Long-Acting HIV Treatment Market in Africa

The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in Africa

Long-Acting HIV Treatment in Africa: rules, payment and research

The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.⁠[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3], SAHPRA (South Africa)⁠[4] and NAFDAC (Nigeria)⁠[5]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[6], the SHA (Kenya)⁠[7], planned National Health Insurance (South Africa)⁠[8] and out of pocket and the NHIA (Nigeria)⁠[9]. ClinicalTrials.gov lists 15 studies on Long-Acting HIV Treatment that are recruiting, active or about to start in Africa.⁠[10]

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] NAFDAC. Checked 19 Nov 2026.

[6] Universal Health Insurance Authority. Checked 14 Nov 2026.

[7] Social Health Authority. Checked 14 Nov 2026.

[8] National Department of Health. Checked 14 Nov 2026.

[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.

[10] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.

Clinical trials

15 active trials in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco

Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.

Top trial sponsors (worldwide)

  1. ViiV Healthcare 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Gilead Sciences, Inc. 6 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

New HIV infections, people (WHO)
CountryValueYear
Burkina Faso1,6002025
DR Congo23,0002025
Egypt6,3002025
Ethiopia9,5002025
Ghana14,0002025
Kenya14,0002025
Malawi14,0002025
Mali4,4002025
Morocco1,1002025
Mozambique77,0002025
Niger1,5002025
Nigeria64,0002025
South Africa130,0002025
Sudan5,3002025
Tanzania34,0002025
Uganda34,0002025
Zambia23,0002025
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Long-Acting HIV Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Long-Acting HIV Treatment market in Africa?
Placeholder estimate: about $47.4 Mn in 2025, rising to about $273.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Africa growing?
Placeholder estimate: about 21.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Long-Acting HIV Treatment are running in Africa?
15 studies are recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Long-Acting HIV Treatment?
PubMed lists 17 papers on Long-Acting HIV Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Africa

See all

Related on hiv and infectious diseases

See the topic